Centogene Past Earnings Performance
Past criteria checks 0/6
Centogene's earnings have been declining at an average annual rate of -18%, while the Healthcare industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 0.8% per year.
Key information
-18.0%
Earnings growth rate
-9.8%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 0.8% |
| Return on equity | n/a |
| Net Margin | -73.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Centogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 49 | -36 | 46 | 12 |
| 30 Sep 23 | 50 | -38 | 45 | 14 |
| 30 Jun 23 | 51 | -40 | 45 | 15 |
| 31 Mar 23 | 49 | -40 | 44 | 16 |
| 31 Dec 22 | 47 | -39 | 42 | 17 |
| 30 Sep 22 | -15 | -44 | 46 | 20 |
| 30 Jun 22 | 2 | -58 | 49 | 20 |
| 31 Mar 22 | 190 | -44 | 55 | 20 |
| 31 Dec 21 | 42 | -57 | 54 | 19 |
| 30 Sep 21 | 162 | -40 | 59 | 17 |
| 30 Jun 21 | 168 | -24 | 57 | 18 |
| 31 Mar 21 | 126 | -27 | 55 | 17 |
| 01 Jan 21 | 38 | -60 | 49 | 15 |
| 30 Sep 20 | 73 | -30 | 43 | 14 |
| 30 Jun 20 | 49 | -28 | 39 | 11 |
| 31 Mar 20 | 50 | -24 | 35 | 11 |
| 31 Dec 19 | 49 | -21 | 33 | 10 |
| 30 Sep 19 | 44 | -19 | 30 | 9 |
| 30 Jun 19 | 45 | -16 | 30 | 8 |
| 31 Mar 19 | 43 | -13 | 28 | 7 |
| 31 Dec 18 | 40 | -11 | 26 | 6 |
| 30 Sep 18 | 39 | -9 | 23 | 7 |
| 31 Dec 17 | 32 | -5 | 15 | 6 |
| 31 Dec 16 | 28 | -5 | 14 | 6 |
Quality Earnings: 39K is currently unprofitable.
Growing Profit Margin: 39K is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 39K is unprofitable, and losses have increased over the past 5 years at a rate of 18% per year.
Accelerating Growth: Unable to compare 39K's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 39K is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-2.2%).
Return on Equity
High ROE: 39K's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.